Coronavirus
Media briefing

8th January 2021

Subtitles are available for this media briefing. If you require subtitles please ensure you activate them on the device you are using.
COVID-19

Cases since September 2020

5
Active

45
Recoveries

0
Deaths

50
Total Cases
COVID-19

Number of helpline calls
COVID-19

Symptomatic Swabs

5 day moving average of symptomatic swabs over time by date swabbed
COVID-19 Border Testing

23rd November - 20th December 2020
82% Day 13 test uptake

21st December - Present
99.6% Day 13 test uptake

Last 26 cases

15 Day 1 test positive

4 Symptomatic post travel - after Day 1 but before Day 13

3 Day 13 test positive

4 Contacts of cases

NO COMMUNITY SEEDING
COVID-19

Community Vaccination Programme

Two vaccines now designated for use in the Bailiwick

AstraZeneca Vaccine and Pfizer/BioNTech vaccine

- Vaccine shown to be safe
- Vaccine shown to be effective
- Staff training and protocol
- Infrastructure to procure and deliver a vaccine
- Appropriate framework for regulation and indemnity
<table>
<thead>
<tr>
<th>Cohort</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Residents in care homes for older adults and their carers</td>
</tr>
<tr>
<td>2</td>
<td>All those 80 years of age and over and frontline health and social care workers</td>
</tr>
<tr>
<td>3</td>
<td>All those 75 years of age and over</td>
</tr>
<tr>
<td>4</td>
<td>All those 70 years of age and over and clinically extremely vulnerable individuals</td>
</tr>
<tr>
<td>5</td>
<td>All those 65 years of age and over</td>
</tr>
<tr>
<td>6</td>
<td>All individuals aged 16 to 64 years with underlying health conditions which put them at higher risk of serious disease and mortality</td>
</tr>
<tr>
<td>7</td>
<td>All those 60 years of age and over</td>
</tr>
<tr>
<td>8</td>
<td>All those 55 years of age and over</td>
</tr>
<tr>
<td>9</td>
<td>All those 50 years of age and over</td>
</tr>
</tbody>
</table>
AstraZeneca vaccine priming (initial) dose followed by a boosting (second) dose of up to 12 weeks.

PfizerBioNTech vaccine ‘at least 3 weeks’

Data does not exist to support the administration of a second dose of the PfizerBioNTech vaccine more than 6 weeks after the first dose is given and that this extended period of time between doses should only be offered in exceptional circumstances.
COVID-19

Key considerations

Vaccine Timing

**Proposed Plan**

**Category 1 & 2**
- Two dose schedule at 3 / 4 weeks

**Category 3+**
- Possibly 6 week interval between doses (aligns with trial data and WHO recommendation)
### COVID-19 Vaccine Delivery

(Two doses) up to the end of March 2021

<table>
<thead>
<tr>
<th>Cohort</th>
<th>Estimated Numbers</th>
<th>Cumulative Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Residents in care homes for older adults and their carers</td>
<td>1,570</td>
</tr>
<tr>
<td>2</td>
<td>All those 80 years of age and over and frontline health and social care workers</td>
<td>6,350</td>
</tr>
<tr>
<td>3</td>
<td>All those 75 years of age and over</td>
<td>2,310</td>
</tr>
<tr>
<td>4</td>
<td>All those 70 years of age and over and clinically extremely vulnerable individuals</td>
<td>6,450</td>
</tr>
<tr>
<td>5</td>
<td>All those 65 years of age and over</td>
<td>3,770</td>
</tr>
</tbody>
</table>
COVID-19

Alderney and Sark

500 doses of AstraZeneca anticipated in the first vaccine delivery.

Prioritised for Alderney and Sark:

- **Alderney**: 300 doses
- **Sark**: 75 doses
COVID-19

Thank you

And thank you to all our students for working with us over the Christmas period.